Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab

TY - JOUR

T1 - Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab

AU - Kowarik, Markus C.

AU - Hoshi, Muna

AU - Hemmer, Bernhard

AU - Berthele, Achim

N1 - Funding Information: From Klinikum rechts der Isar der Technischen Universität Mün-chen (M.C.K., M.H., B.H., A.B.); and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany. Author contributions: Dr. Kowarik analyzed the data and drafted the manuscript. Dr. Hoshi analyzed the data and revised the manuscript for intellectual content. Dr. Hemmer analyzed the data and revised the manuscript for intellectual content. Dr. Berthele analyzed the data and drafted the manuscript. Study funding: No targeted funding. Disclosure: M.C. Kowarik received travel funding from Merck-Serono, Bayer Health Care, and Novartis, and received research support from Novartis. M. Hoshi received travel funding from Bayer Health Care, Biogen Idec, and Merck Serono. M. Hemmer served on the scientific advisory board for Bayer, Biogen Idec, Roche, Novartis, Merck Serono, Chugai, GSK, and Genentech; received travel funding and/or speaker honoraria from Bayer, Biogen Idec, Roche, No-vartis, and Merck Serono; is on the editorial board for Archives of Neurologie, Experimental Neurology, and MS Journal; holds a patent for anti-KIR4.1 antibody testing in MS, Genetic factors influencing the development of NABs; has consulted for Gerson Lehrman Group; and received research support from Bayer, Biogen Idec, Roche, Novartis, Merck Serono, Metanomics, Chigai, Deutsche Forschungs-gemeinschaft, Bundesministerium fur Bildung und Forschung, European Community, Competence Network for Multiple Sclerosis Synergy Excellence Cluster, and German Research Foundation. A. Berthele received travel funding and/or speaker honoraria from Biogen Idec, Merck Serono, Novartis, Teva, and Bayer; and received research support from Bayer. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. Received October 19, 2015. Accepted in final form December 23, 2015.

PY - 2016/4/1

Y1 - 2016/4/1

UR - https://www.scopus.com/pages/publications/85023194381

U2 - 10.1212/NXI.0000000000000208

DO - 10.1212/NXI.0000000000000208

M3 - Article

AN - SCOPUS:85023194381

SN - 2332-7812

VL - 3

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

IS - 2

M1 - e208

ER -